NASDAQ · NCEL
Healthcare · Biotechnology
$3.60
Down-$0.31 (-8.47%)
Updated Aug 14, 2026, 5:19 PM
SID Score
4.1/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 21 trading sessions · Daily adjusted prices
NCEL closed at $3.60 after 21 trading sessions, down 7.93% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 13, 2026 | $3.33 | $3.60 | $3.225 | $3.60 | 7.81K |
| Aug 12, 2026 | $3.13 | $3.35 | $3.13 | $3.33 | 2.67K |
| Aug 11, 2026 | $3.235 | $3.25 | $3.09 | $3.19 | 17.8K |
| Aug 10, 2026 | $3.20 | $3.32 | $3.16 | $3.25 | 14.51K |
| Aug 7, 2026 | $3.28 | $3.335 | $3.235 | $3.31 | 4.46K |
| Aug 6, 2026 | $3.36 | $3.60 | $3.27 | $3.34 | 20.8K |
| Aug 5, 2026 | $3.54 | $3.75 | $3.49 | $3.56 | 5.97K |
| Aug 4, 2026 | $3.585 | $3.74 | $3.3601 | $3.45 | 5.71K |
| Aug 3, 2026 | $3.61 | $3.725 | $3.42 | $3.42 | 16.18K |
| Jul 31, 2026 | $3.44 | $3.68 | $3.36 | $3.49 | 10.14K |
| Jul 30, 2026 | $3.48 | $3.63 | $3.15 | $3.3614 | 9.73K |
| Jul 29, 2026 | $3.54 | $3.7463 | $3.50 | $3.52 | 9.56K |
| Jul 28, 2026 | $3.59 | $3.6499 | $3.48 | $3.48 | 9.28K |
| Jul 27, 2026 | $3.70 | $3.765 | $3.41 | $3.60 | 7.29K |
| Jul 24, 2026 | $3.69 | $3.755 | $3.65 | $3.755 | 6.08K |
| Jul 23, 2026 | $3.70 | $3.80 | $3.66 | $3.80 | 13.05K |
| Jul 22, 2026 | $3.76 | $3.7999 | $3.65 | $3.65 | 5.66K |
| Jul 21, 2026 | $3.84 | $3.9518 | $3.75 | $3.81 | 12.35K |
| Jul 20, 2026 | $4.16 | $4.16 | $3.65 | $3.97 | 15.15K |
| Jul 17, 2026 | $3.84 | $4.155 | $3.70 | $4.09 | 14.22K |
| Jul 16, 2026 | $3.85 | $3.995 | $3.66 | $3.91 | 19.85K |
The latest Smart Investors Daily articles mentioning NCEL.
NCEL research
Company profile and research snapshot.
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Laidlaw & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Jul 15, 2026
NewcelX Ltd. (("NewcelX", NASDAQ:NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, today announced that the Brazilian Patent and Trademark Office has issued Patent
Benzinga · Jul 13, 2026
Laidlaw & Co. analyst Yale Jen initiates coverage on NewcelX (NASDAQ:NCEL) with a Buy rating and announces Price Target of $23.
Benzinga · Jul 1, 2026
The FDA provided clarity regarding the regulatory pathway toward launching a clinical trial of NCEL-101 for type 1 diabetes in combination with Eledon Pharmaceuticals’ (NASDAQ:ELDN) anti-CD40L antibody, tegoprubart, an
Benzinga · Jun 15, 2026
The publication further validates NewcelX's ability to develop novel cell therapies through its stem cell technology platform, designed to generate scalable therapeutic assets across multiple applications.The full paper
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning NCEL.
